Can the accepting foreign clinical data policy improve innovation investment of pharmaceutical firms? Empirical evidence from China
{{output}}
Introduction: In October 2017, China initiated adjustments to the registration procedures for imported drugs to promote accessibility to overseas drugs. In support of this decision, the National Medical Products Administration (N... ...
